BC3402 injection

DRUG2 trials

Sponsors

Biocity Biopharmaceutics Co., Ltd.

Conditions

Hematologic MalignancyHepatocellular Carcinoma

Phase 1

A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Biocity Biopharmaceutics Co., Ltd.Hematologic Malignancy

Start: 2023-07-06End: 2024-06-15Target: 13Updated: 2023-07-24

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Not yet recruitingNCT06111326

Biocity Biopharmaceutics Co., Ltd.Hepatocellular Carcinoma

Start: 2023-10-31End: 2026-05-31Target: 83Updated: 2023-11-01